Ran Wang | Pulmonary Hypertension | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Ran Wang | Pulmonary Hypertension | Best Researcher Award

First Affiliated Hospital of Anhui Medical University | China

Dr. Ran Wang is an accomplished respiratory medicine researcher whose work has significantly advanced the understanding of pulmonary hypertension and chronic obstructive pulmonary disease (COPD). With more than two decades of clinical and scientific experience, he has extensively investigated the molecular mechanisms underlying hypoxic pulmonary hypertension and COPD pathogenesis. His research has contributed to improved insights into vascular remodeling, inflammatory signaling, and pulmonary vascular resistance, helping to strengthen the scientific basis for future diagnostic and therapeutic strategies.

He has successfully led multiple high-impact research projects, including two funded by the National Natural Science Foundation and three additional provincial-level studies. His work spans basic, translational, and clinical domains, integrating experimental models with patient-centered research to address key challenges in pulmonary vascular diseases. He has authored or co-authored 59 peer-reviewed journal articles, including over 50 SCI-indexed publications and more than 20 as first or corresponding author. His research outputs include four patents related to respiratory disease mechanisms and clinical application innovations.

In addition to his scholarly publications, he serves on editorial boards of leading journals such as Journal of Cancer Research and Clinical Oncology, BMC Pulmonary Medicine, and Cancer Control, contributing to the advancement of scientific discourse in respiratory and cancer research.

Profile: Scopus

Featured Publications:

  • Han, R., Guan, Y., Li, P., Tang, M., Fei, G., Zeng, D., & Wang, R. (2025). Real-world efficacy of oral azvudine in hospitalized patients with COVID-19: A multicenter retrospective cohort study. Journal of Infection and Public Health, 18(12), 102987.

  • Liu, Y., Wang, R., & Jiang, T. (2025). RNA-binding proteins as a molecular link between COPD and pulmonary hypertension. International Journal of Medical Sciences, 22(8), 1979–1991.

  • Rao, B., Wang, D., Yang, M., … et al. (2025). Real-world effectiveness and safety of oral Azvudine versus Paxlovid for COVID-19 in patients with kidney disease: A multicenter, retrospective, cohort study. BMC Infectious Diseases, 25, 275.

 

 

 

Wan Wan Lin | Inflammation | Best Researcher Award

Published on by Cell Biologist

Prof. Wan Wan Lin | Inflammation | Best Researcher Award

Department of Pharmacology, College of Medicine, NTU | Taiwan

Dr. Wan-Wan Lin is a leading researcher in the fields of pharmacology and immunology, with a strong focus on cellular signaling and innate immune mechanisms. Her work has significantly advanced understanding of signal transduction pathways and their regulation of inflammation and cell death. She has made notable contributions to the study of pattern recognition receptors, inflammasomes, and cytokine-mediated immune responses, particularly in the context of oxidative stress and mitochondrial function. Dr. Lin’s research explores how mitochondrial dynamics and redox balance influence inflammatory signaling and programmed cell death, providing key insights into the molecular basis of immune regulation and inflammatory diseases. Her studies have also shed light on the crosstalk between cellular stress responses and immune activation, offering potential therapeutic targets for controlling excessive inflammation and tissue damage. Recognized for her excellence in research, Dr. Lin has received multiple national awards and continues to contribute to the advancement of pharmacological sciences through her editorial and academic roles. Her integrative approach bridges pharmacology, immunology, and cell biology, driving innovations in the understanding of molecular mechanisms underlying inflammation and innate immunity.

Profile: Orcid

Featured Publications:

Lin, W.-W., Lee, C.-Y., Tsai, M.-C., & Tsaur, M.-L. (1985). Pharmacological study on angusticeps-type toxins from mamba snake venoms. Journal of Pharmacology and Experimental Therapeutics, 233, 491–498.

Lin, W.-W., Chang, P.-L., Lee, C.-Y., & Joubert, F. J. (1987). Pharmacological study on phospholipases A₂ isolated from Naja mossambica mossambica venom. Proceedings of the National Science Council, Republic of China B, 11, 155–163.

Lin, W.-W., Lee, C.-Y., & Burnett, J. W. (1988). Effect of sea nettle (Chrysaora quinquecirrha) venom on isolated rat aorta. Toxicon, 26, 1209–1212.

Chiou, S.-H., Lin, W.-W., & Chang, W.-P. (1989). Sequence characterization of venom toxins from Thailand cobra. International Journal of Peptide and Protein Research, 34, 148–152.

Lee, C.-Y., Lin, W.-W., Chen, Y.-M., & Lee, S.-Y. (1989). Is direct cardiotoxicity the primary cause of death following intravenous injection of the basic phospholipase A₂ from Naja nigricollis venom? Acta Physiologica et Pharmacologica Latinoamericana, 39, 383–391.

Lee, C.-Y., & Lin, W.-W. (1989). Two subtypes of acetylcholinesterase isoenzymes distinguishable by Angusticeps-type toxin F7. Comparative Biochemistry and Physiology Part C: Comparative Pharmacology and Toxicology, 92, 279–281.

Lin, W.-W., Lee, C.-Y., & Chuang, D.-M. (1989). Cross-desensitization of endothelin- and sarafotoxin-induced phosphoinositide turnover in neurons. European Journal of Pharmacology, 166, 581–582.

Lin, W.-W., Chen, Y.-M., Lee, S.-Y., Nishio, H., Kimura, T., Sakakibara, S., & Lee, C.-Y. (1990). Cardiovascular effects of two disulfide analogues of sarafotoxin S6b. Toxicon, 28, 911–923.

Lin, W.-W., Lee, C.-Y., Yasumoto, T., & Chuang, D.-M. (1990). Maitotoxin induces phosphoinositide turnover and modulates glutamatergic and muscarinic cholinergic receptor function in cultured cerebellar neurons. Journal of Neurochemistry, 55, 1563–1568.

Lin, W.-W., & Lee, C.-Y. (1990). Biphasic effects of endothelin in the guinea-pig ileum. European Journal of Pharmacology, 176, 57–62.

Yuxiang Wang | Molecular Biology | Best Researcher Award

Published on by Cell Biologist

Dr. Yuxiang Wang | Molecular Biology | Best Researcher Award

Dr. Yuxiang Wang, Fudan University, China

Dr. Yuxiang Wang is a Principal Investigator and Ph.D. Supervisor at Fudan University, with an extensive background in molecular biology, oncology, and translational medicine. He earned his Ph.D. in Developmental and Molecular Biology from the Albert Einstein College of Medicine, where he worked under the mentorship of Dr. Jeffrey W. Pollard. Following this, he completed a prestigious research fellowship at Memorial Sloan-Kettering Cancer Center. Dr. Wang has built a strong academic and clinical research portfolio, focusing on gliomas and muscular dystrophy. His work utilizes state-of-the-art preclinical models and CRISPR screening technologies to identify novel therapeutic strategies. Dr. Wang is a recipient of numerous honors, including the MSK Society Scholar Award and Shanghai Leading Overseas Talent recognition. He actively collaborates with clinicians to translate lab discoveries into patient therapies, and his prolific publication record reflects deep scientific rigor and innovation.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Strong Research Track Record
    Dr. Wang has published in top-tier journals such as Nature Communications, Science Advances, Cancer Research, and PNAS. His publication record demonstrates consistency, depth, and high impact across multiple domains including glioma biology and gene therapy.

  2. Dual Research Focus
    He leads research in two distinct yet critical biomedical areas—malignant gliomas and muscular dystrophy. This breadth shows versatility and the ability to manage complex translational programs.

  3. Innovative Techniques
    Dr. Wang effectively applies CRISPR-based genetic screening, preclinical mouse models, and patient-derived cell lines—cutting-edge tools that reflect a forward-thinking, high-tech research approach.

  4. International Research Background
    His training and professional experience in both the U.S. (at Memorial Sloan-Kettering Cancer Center) and China make him a bridge between Western and Eastern biomedical research ecosystems.

  5. Leadership and Mentorship
    Serving as both Principal Investigator and Ph.D. Supervisor, and having been Vice Director at a major clinical research center, Dr. Wang shows strong leadership and a commitment to research training.

  6. Recognitions and Awards
    Prestigious honors such as the Shanghai Leading Overseas Talent, Shanghai Pujiang Talent, and MSK Society Scholar Award (twice) underline peer recognition and scientific excellence.

🛠️ Areas for Improvement:

  1. Clinical Translation and Implementation
    While his preclinical work is strong, more details or evidence on how these findings have progressed toward clinical trials or therapeutic products could further strengthen his translational profile.

  2. Interdisciplinary Collaborations
    Expanding collaborations across fields like bioengineering, immunotherapy, or computational biology may add further value and broaden research impact.

  3. Visibility and Outreach
    Increasing visibility through keynote lectures, patents, or public datasets could enhance his reputation globally and support broader dissemination of his work.

  4. Grants and Funding Portfolio
    While not detailed in the CV, highlighting national/international grant leadership or participation would provide insight into his ability to secure and manage competitive research funding.

🎓 Education:

Dr. Yuxiang Wang holds a distinguished academic background across leading institutions. He completed his Ph.D. in Developmental and Molecular Biology at Albert Einstein College of Medicine (2008–2014), under Dr. Jeffrey W. Pollard, focusing on hormone signaling and uterine biology. Before that, he earned a Master of Sciences from Fudan University (2004–2007), mentored by Dr. Bo Chen, where he explored hormone interactions in reproductive biology. He began his academic journey with a Bachelor of Sciences from the Ocean University of China (2000–2004), majoring in life sciences. This robust education laid the foundation for his later success in cancer biology and translational research. Throughout his academic path, Dr. Wang has demonstrated a consistent focus on the cellular and molecular mechanisms underlying human diseases, especially cancer and genetic disorders. His education, blending rigorous laboratory work and clinical relevance, has uniquely positioned him for cutting-edge biomedical research.

💼 Experience:

Dr. Wang currently serves as Principal Investigator and Ph.D. Supervisor at Fudan University’s School of Basic Medical Sciences (2020–present), where he leads research on gliomas and muscular dystrophy. From 2021 to 2023, he also held the position of Vice Director of the Research Department at the Clinical Research Center of the Affiliated Children’s Hospital of Fudan University, coordinating clinical and translational projects. Prior to his return to China, Dr. Wang worked as a Research Fellow at Memorial Sloan-Kettering Cancer Center (2015–2020), collaborating with Dr. Timothy Chan and Dr. Jason Huse on the molecular basis of brain tumors and treatment resistance. His career bridges fundamental science and clinical applications, with a focus on leveraging genetic models and CRISPR technologies to uncover therapeutic targets. Dr. Wang’s international experience and leadership in high-impact research programs underscore his contributions to biomedical innovation and mentorship.

🏅 Awards and Honors:

Dr. Yuxiang Wang’s outstanding scientific contributions have been recognized through several prestigious awards. He was named a Shanghai Leading Overseas Talent (2020) and a Shanghai Pujiang Talent (2020), highlighting his excellence in international scientific exchange and leadership. While at Memorial Sloan-Kettering Cancer Center, he was twice awarded the MSK Society Scholar Award (2018, 2019), which recognizes exceptional postdoctoral researchers demonstrating strong potential for independent academic careers. These accolades underscore Dr. Wang’s commitment to impactful research, innovation in therapeutic development, and mentorship of young scientists. His ability to translate fundamental research into preclinical and potentially clinical solutions sets him apart as a research leader. These honors reflect peer recognition of both the depth and translational potential of his work in oncology and genetic diseases.

🔬 Research Focus:

Dr. Wang’s research centers on two critical areas: malignant gliomas and muscular dystrophy. In glioma studies, his team investigates the cooperative role of IDH and ATRX mutations using CRISPR-based genetic screening in mouse models to identify synthetic lethal targets—genes whose inhibition can selectively kill tumor cells with specific mutations. This strategy opens doors to novel, mutation-specific therapies with minimal harm to healthy cells. In muscular dystrophy, Dr. Wang focuses on rare genetic mutations affecting glycosylation pathways, utilizing patient-derived cells and animal models to evaluate gene therapy and genome editing solutions. His work seeks not only to understand disease mechanisms but also to bridge the lab-to-clinic gap. A long-term objective is to offer personalized therapies for patients with genetically defined diseases. The integration of molecular biology, translational research, and therapeutic innovation defines his approach.

📚 Publication Top Notes: 

  1. 🧬 Genetically Engineered Mouse Models Unveil Mechanisms and Therapeutic Strategies for GMPPB-Associated Dystroglycanopathy – Nature Communications (under revision)

  2. 🧠 PRICKLE4 Underlies IDH mutant Tumor Resistance against PARP Inhibition – Advanced Science (under revision)

  3. 🧫 Comprehensively characterizing eRNA in immune cells to screen combinational strategies for anti-cancer immunotherapy – Cancer Research (2025)

  4. 🔬 Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas – Science Advances

  5. 🧬 G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma – Nature Communications

  6. 🧪 Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence – Nature Genetics

  7. 🧠 Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling – Nature Communications

  8. 🧬 Activation of protein synthesis in mouse uterine epithelial cells by estradiol-17β is mediated by a PKC–ERK1/2–mTOR signaling pathway – PNAS

  9. 🔬 GSK-3β mediates in the progesterone inhibition of estrogen-induced cyclin D2 nuclear localization and cell proliferation in cyclin D1−/− mouse uterine epithelium – FEBS Letters

🧾 Conclusion:

Dr. Yuxiang Wang is a highly deserving candidate for the Best Researcher Award. He demonstrates:

  • A clear and sustained record of scientific excellence,

  • Deep expertise in cancer biology and rare disease genetics,

  • Use of innovative methodologies, and

  • Leadership in both academic and clinical research environments.

His contributions to understanding the molecular basis of gliomas and developing targeted therapies for muscular dystrophy have significant implications for personalized medicine. With continued development in clinical translation and interdisciplinary reach, he stands out as a leader of the next generation of biomedical scientists.

Jianli GAO | Mitochondrial Function Dynamics | Best Researcher Award

Published on by Cell Biologist

Prof. Jianli GAO | Mitochondrial Function Dynamics | Best Researcher Award

Prof. Jianli GAO , School of Pharmaceutical Sciences, Zhejiang Chinese Medical University , China

Professor Jian-Li Gao is a distinguished researcher in Immunology and Tumor Pharmacology at Zhejiang Chinese Medical University (ZCMU), China. With a solid academic background in Traditional Chinese Medicine and Biomedical Sciences, she has carved a unique path by integrating traditional practices with modern biomedical research. After earning her Ph.D. from the University of Macau and completing a postdoctoral fellowship at the University of Chicago, she returned to ZCMU, where she now serves as a Professor and Director of the CTMP editorial office. She also holds the title of Editor-in-Chief of the Journal of Experimental and Clinical Application of Chinese Medicine. Known for her impactful studies on thymic immunity, mitochondrial transfer, and age-related immune degeneration, Prof. Gao has authored numerous high-impact papers and led several nationally funded projects. Her dedication, scientific acumen, and leadership make her an ideal candidate for recognition as a top-tier researcher.

Publication Profile:

Scopus

Strengths for the Award:

  1. 📚 Extensive Publication Record

    • Published high-impact research in top-tier journals like Phytomedicine, International Journal of Molecular Sciences, Molecules, and Journal of Ethnopharmacology.

    • Topics span immunosenescence, mitochondrial transfer, alopecia regeneration, and TCM pharmacology—an excellent multidisciplinary focus.

  2. 🔬 Innovative Research Focus

    • Focuses on cutting-edge topics like tunneling nanotube-mediated mitochondrial transfer and immune rejuvenation—a unique and relevant field in aging and cancer research.

    • Integration of Traditional Chinese Medicine (TCM) with modern immunology and pharmacology shows her ability to bridge ancient knowledge with new technologies.

  3. 🌍 International Exposure

    • Completed a postdoctoral fellowship at the University of Chicago, demonstrating global collaboration and adaptability in high-caliber environments.

  4. 🎓 Academic and Editorial Leadership

    • Editor-in-Chief of a peer-reviewed journal and Editorial Board Member of Scientific Reports.

    • Director of CTMP editorial office and a key figure in shaping academic publishing within her university.

  5. 💡 Research Funding Success

    • Principal Investigator of multiple NSFC-funded projects (highly competitive in China), totaling over ¥1,000,000 in research grants.

  6. 🧑‍🏫 Academic Career Progression

    • Rapid professional growth from Assistant Professor to Full Professor in under 10 years—shows high competence, leadership, and recognition by peers.

Areas for Improvement:

  1. 🏅 Documentation of Individual Honors/Awards

    • While her academic and publishing roles speak volumes, a clearer list of individual recognitions, national awards, or innovation prizes would strengthen the case further.

  2. 🌐 Global Research Collaborations

    • Though she has worked internationally, further multi-country clinical collaborations or EU/NIH projects would expand her global footprint.

  3. 🗣 Public Engagement & Outreach

    • Amplifying her presence through conferences, workshops, and keynote speeches, particularly internationally, could further solidify her status as a global thought leader.

🎓 Educational Background:

Prof. Jian-Li Gao pursued her academic training in Traditional Chinese Medicine and Biomedical Sciences, blending traditional knowledge with cutting-edge medical research. She obtained her Bachelor’s degree in Traditional Chinese Medicine (2003) from Zhejiang Chinese Medical University (ZCMU). She continued her studies at the University of Macau, earning a Master’s degree in Chinese Medicinal Science (2005) and a Ph.D. in Biomedical Sciences (2009) from the Institute of Chinese Medical Sciences. Her doctoral work focused on cellular mechanisms and immune pharmacology, laying the foundation for her future research career. Her education uniquely positioned her to investigate immune regulation through both modern biomedical techniques and the traditional principles of Chinese medicine. The fusion of these approaches underpins her scientific contributions and helps advance integrative medical research both in China and internationally.

💼 Professional Experience: 

Prof. Gao has over 14 years of experience in academic research and teaching at Zhejiang Chinese Medical University. Starting as an Assistant Professor (2011–2013), she was promoted to Associate Professor (2013–2018) and has held the title of Professor since 2019. Her international exposure includes a postdoctoral fellowship at the University of Chicago, where she deepened her expertise in tumor pharmacology and immunology. Prof. Gao currently directs the CTMP English Editorial Office at ZCMU and serves as the Editor-in-Chief of a leading Chinese medicine journal. She also contributes as a Board Member of Scientific Reports and a young editorial board member for Chinese Medicine. Throughout her tenure, she has led numerous national research projects, mentored students, and facilitated cross-disciplinary collaborations. Her trajectory reflects a consistent pattern of academic growth, leadership, and contribution to the global scientific community.

🏅 Awards and Honors:

Though specific awards are not explicitly listed in the provided information, Prof. Jian-Li Gao’s numerous appointments and leadership roles are strong indicators of her recognition in the academic field. She is the Editor-in-Chief of the Journal of Experimental and Clinical Application of Chinese Medicine, a prestigious role typically reserved for top researchers in the discipline. Her role as Director of the CTMP editorial office and her inclusion as a Board Member of Scientific Reports and Young Editorial Board Member for Chinese Medicine signal national and international acknowledgment of her scientific contributions. She has also successfully led multiple National Natural Science Foundation of China (NSFC) projects, a competitive funding body in China, which highlights her research’s credibility and impact. These honors collectively reflect her excellence in scientific innovation, editorial leadership, and her commitment to advancing Chinese and integrative medicine.

🔬 Research Focus:

Prof. Jian-Li Gao’s research centers on thymic immune senescence, mitochondrial transfer, and the pharmacological effects of Traditional Chinese Medicine (TCM) on immune system regulation. She explores how compounds such as Epimedin C, Thymosin β15, and Ligustilide can delay thymus degeneration, enhance mitochondrial functionality, and promote immune resilience—especially in contexts such as menopause, aging, and cancer. Her work bridges the gap between TCM and modern molecular biology, applying cell biology techniques to understand how herbal extracts affect immune cell signaling, cytoskeletal dynamics, and tissue repair. A unique aspect of her work is the use of mitochondrial transfer via tunneling nanotubes, a cutting-edge concept in immunopharmacology. With a holistic approach, she aims to uncover therapeutic strategies rooted in TCM that are evidence-based and translational. Her research has major implications in autoimmune diseases, aging, regenerative medicine, and oncology.

📚 Publications Top Notes:

  1. 📖 Epimedin C promotes mitochondrial transfer and delays thymus atrophy in 4-VCD induced mimetic-menopausal mice – Phytomedicine, 2025

  2. 📖 Dermal T cell immunity and key regulatory signaling pathways: Implications in immune-mediated alopecia and hair regeneration – Genes & Diseases, 2025

  3. 📖 Linderae Radix extract attenuates ulcerative colitis by inhibiting the JAK/STAT signaling pathway – Phytomedicine, 2024

  4. 📖 Ligustilide prevents thymic immune senescence by regulating Thymosin β15-dependent spatial distribution of thymic epithelial cells – Phytomedicine, 2024

  5. 📖 Thymosin β4 regulates the differentiation of thymocytes by controlling the cytoskeletal rearrangement and mitochondrial transfer – IJMS, 2024

  6. 📖 Th22 is the effector cell of Thymosin β15-induced hair regeneration in mice – Inflammation and Regeneration, 2024

  7. 📖 Ruyong Formula improves thymus function of CUMS-stimulated breast cancer mice – Journal of Ethnopharmacology, 2024

  8. 📖 Age-related hearing loss and its potential drug candidates: a systematic review – Chinese Medicine, 2023

  9. 📖 Treatment of Generalized Anxiety Disorder with nose-to-brain drug delivery of natural drugs – J. Exp. & Clin. App. of Chinese Medicine, 2023

  10. 📖 Thymosin α1 and its role in viral infectious diseases: Mechanism and clinical application – Molecules, 2023

📝 Conclusion:

Professor Jian-Li Gao is highly deserving and exceptionally well-qualified for the Best Researcher Award. Her research is innovative, translational, and impactful, particularly in the intersection of Traditional Chinese Medicine and modern immunology. She has demonstrated consistent academic excellence, leadership in editorial work, and obtained national-level competitive funding.